Subsidy Information and Financing Scheme MAFFaricimab (Vabysmo) Injection 6 mg/0.05 mL 1) Treatment of adults with visual impairment due to neovascular (wet) age-related macular degenera... See all × MAFFaricimab (Vabysmo) Injection 6 mg/0.05 mL 1) Treatment of adults with visual impairment due to neovascular (wet) age-related macular degeneration. 2) Treatment of adults with visual impairment due to diabetic macular oedema.
Drug Guidance for Subsidy 02/01/2024 Anti-vascular endothelial growth factors for treating diabetic macular oedema and age-related macular degeneration The Ministry of Health’s Drug Advisory Committee has recommended: Faricimab 6 mg/0.05 mL vial... See all × 02/01/2024 Anti-vascular endothelial growth factors for treating diabetic macular oedema and age-related macular degeneration The Ministry of Health’s Drug Advisory Committee has recommended: Faricimab 6 mg/0.05 mL vial for treating adults with visual impairment due to: diabetic macular oedema; and neovascular (wet) age-related macular degeneration. Funding status RFaricimab 6 mg/0.05 mL vial is recommended for inclusion on the MOH Medication Assistance Fund (MAF) for the abovementioned indications from 1 March 2024. NRMAF assistance does not apply to any formulations or strengths of aflibercept for treating diabetic macular oedema or neovascular age-related macular degeneration.
General Availability in Public Healthcare Institution Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration Vabysmo Injection 6 mg/0.05 mL Alexandra Hospital Khoo Teck Puat Hospital Ng Teng Fong General Hospital National University Hospital Singapore National Eye Centre Tan Tock Seng Hospital Woodlands Health Campus
INTRAVITREOUS Select a brand starting with the letter: V VABYSMO SOLUTION FOR INJECTION 6MG/0.05ML [SIN16514P]